Latest News

Will the new Alzheimer’s drug put pressure on Medicare premiums?

The FDA approved the drug Leqembi, and Medicare will cover the new expensive new drug that promises the slowing the advance of Alzheimer’s disease. Although the last Alzheimer’s disease drug caused Medicare Part B premiums to rise an incredible 14.5 percent, it will be different this time. However, the expected cost of $26,500 per year per patient; will put new pressure on Medicare premiums. Mark Miller explains how Leqembi will add cost pressures for Medicare. Read Mr. Miller’s article here…

This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.

Website by Geiger Computers